Quantcast
Last updated on April 16, 2014 at 8:56 EDT

Latest Enzyme inhibitor Stories

2013-03-26 08:29:06

NEWARK, Del., March 26, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced the addition of its proprietary iBioLaunch(TM)-produced recombinant C1 esterase inhibitor to the group of product candidates selected for clinical development by the Company and its collaborators. Other candidates currently undergoing tests required for Investigational New Drug Applications with the FDA include an undisclosed iBioLaunch-produced monoclonal antibody and vaccines for anthrax, malaria, and...

2012-06-11 11:53:36

Technique will help scientists understand how cells' common sugar molecules influence inflammation, cancer metastasis, and related conditions Scientists at The Scripps Research Institute have developed chemical compounds that can make key modifications to common sugar molecules ("glycans"), which are found on the surface of all cells in our body. The new study presents powerful new tools for studying these molecules' function, for example in cell signaling and immunity, and for...

2011-11-17 06:00:00

NEWARK, Del., Nov. 17, 2011 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced that it successfully used its proprietary iBioLaunch technology to produce full length as well as a modified form of C1 esterase inhibitor in green plants. Plasma-derived C1 esterase inhibitor is an Orphan Drug approved by the FDA to treat or prevent the symptoms of hereditary angioedema (HAE), an inherited disorder caused by low levels of C1 esterase inhibitor that causes swelling of the face, hands,...

2011-10-31 10:22:31

In a technical tour de force, scientists at Fox Chase Cancer Center have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 enzymes, including enzymes critical for cancer and other diseases. Additionally, a free library of the results has been made available online to the research community. This unique library represents an important new tool for accelerating the development of an entire class of targeted cancer drugs. The...

2011-05-06 14:25:04

Cancer researchers at UT Southwestern Medical Center are helping unlock the cellular-level function of the telomerase enzyme, which is linked to the disease's growth. Their latest findings, published today in Molecular Cell, demonstrate that telomerase repairs chromosomes in one of two ways "“ depending on whether a cell is dividing normally or if the cell is under stress from enzyme inhibition "“ and could lead to new or improved cancer-fighting therapies that promote inhibition...

2011-04-11 16:00:45

Virtually all processes in the human body rely on a unique class of proteins known as enzymes. To study them, scientists want to attach these molecules to surfaces and hold them fast, but this can often be a tricky undertaking. Now Jinglin Fu and his colleagues at the Biodesign Institute at Arizona State University have developed a superior method for immobilizing enzymes on surfaces, deftly controlling their orientation, improving their efficiency and rendering them more stable. The group's...

2011-03-28 17:26:56

Study in mice highlights alternative anti-inflammatory approach to epilepsy management If common anticonvulsant drugs fail to manage epileptic seizures, then perhaps the anti-inflammatory* route is the way to go. That's according to Mattia Maroso and colleagues from the Mario Negri Institute for Pharmacological Research in Milan, Italy, who found that giving mice repeated doses of a specific enzyme inhibitor significantly reduced both chronic epileptic activity and acute seizures. Their...

2010-11-29 12:48:15

Publication in Nature Chemical Biology demonstrates that irreversible covalent inhibition can increase selectivity, potency and duration of action, broadens applications for targeted covalent drugs to the protease gene family Avila Therapeuticsâ“ž¢, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a...